An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17

Cytokine and Growth Factor Reviews

Volumn 26, Issue 1, 2015, Pages 25-33

  Grine, Lynda ^a,b   Dejager, Lien ^a,b   Libert, Claude ^a,b   Vandenbroucke, Roosmarijn E ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

IL 17 IL 23; Psoriasis; TNF; Tumor necrosis factor; Type I interferons

Indexed keywords

ANTIPSORIASIS AGENT; BRODALUMAB; ETANERCEPT; GR 7624; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12P35; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 17F; INTERLEUKIN 19; INTERLEUKIN 2; INTERLEUKIN 20; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 24; INTERLEUKIN 3; IXEKIZUMAB; NI 1401; PROTEIN P75; SECUKINUMAB; SIFALIMUMAB; STAT4 PROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; AUTACOID; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; AUTOIMMUNE DISEASE; CELL MOTILITY; CHRONIC DISEASE; CYTOKINE PRODUCTION; HUMAN; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN FUNCTION; PSORIASIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TH17 CELL; ANIMAL; IMMUNOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; HUMANS; INFLAMMATION MEDIATORS; INTERFERON TYPE I; INTERLEUKIN-17; INTERLEUKIN-23; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84922879674     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2014.10.009     Document Type: Review

References (99)

1. Fredriksson T., Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978, 157(4):238-244.
2. Moustou A.-E., Matekovits A., Dessinioti C., Antoniou C., Sfikakis P.P., Stratigos A.J. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol 2009, 61(3):486-504. 10.1016/j.jaad.2008.10.060.
3. Antoni C., Braun J. Side effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol 2002, 20:S152-S157. (6 Suppl 28):.
4. Balakumar P., Singh M. Anti-tumour necrosis factor-alpha therapy in heart failure: future directions. Basic Clin Pharmacol Toxicol 2006, 99(6):391-397. 10.1111/j.1742-7843.2006.pto_508.x.
5. Kerbleski J.F., Gottlieb A.B. Dermatological complications and safety of anti-TNF treatments. Gut 2009, 58(8):1033-1039. 10.1136/gut.2008.163683.
6. Almoallim H., Al-Ghamdi Y., Almaghrabi H., Alyasi O. Anti-tumor necrosis factor-α induced systemic lupus erythematosus. Open Rheumatol J 2012, 6:315-319. 10.2174/1874312901206010315.
7. Debandt M., Vittecoq O., Descamps V., Le Loët X., Meyer O. Anti-TNF-alpha-induced systemic lupus syndrome. Clin Rheumatol 2003, 22(1):56-61. 10.1007/s10067-002-0654-5.
8. Iborra M., Beltrán B., Bastida G., Aguas M., Nos P. Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect. J Crohns Colitis 2011, 5(2):157-161. 10.1016/j.crohns.2010.11.001.
9. Barthel C., Biedermann L., Frei P., Vavricka S.R., Kündig T., Fried M., et al. Induction or exacerbation of psoriasis in patients with Crohn's disease under treatment with anti-TNF antibodies. Digestion 2014, 89(3):209-215. 10.1159/000358288.
10. Paradowska-Gorycka A., Wojtecka-Lukasik E., Trefler J., Wojciechowska B., Lacki J.K., Maslinski S. Association between IL-17F gene polymorphisms and susceptibility to and severity of rheumatoid arthritis (RA). Scand J Immunol 2010, 72(2):134-141. 10.1111/j.1365-3083.2010.02411.x.
11. Seiderer J., Elben I., Diegelmann J., Glas J., Stallhofer J., Tillack C., et al. Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm Bowel Dis 2008, 14(4):437-445. 10.1002/ibd.20339.
12. Spadaro A., Lubrano E. Beyond anti-TNF-α agents in psoriatic arthritis. Expert Rev Clin Immunol 2013, 9(6):507-509. 10.1586/eci.13.32.
13. Clarke A.W., Poulton L., Wai H.Y., Walker S.A., Victor S.D., Domagala T., et al. A novel class of anti-IL-12p40 antibodies: potent neutralization via inhibition of IL-12-IL-12Rβ2 and IL-23-IL-23R. MAbs 2010, 2(5):539-549. 10.4161/mabs.2.5.13081.
14. Toichi E., Torres G., McCormick T.S., Chang T., Mascelli M.A., Kauffman C.L., et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol 2006, 177(7):4917-4926.
15. Pasparakis M., Alexopoulou L., Episkopou V., Kollias G. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 1996, 184(4):1397-1411.
16. Le Hir M., Bluethmann H., Kosco-Vilbois M.H., Müller M., di Padova F., Moore M., et al. Tumor necrosis factor receptor-1 signaling is required for differentiation of follicular dendritic cells, germinal center formation, and full antibody responses. J Inflamm 1995-1996, 47(1-2):76-80.
17. Ettehadi P., Greaves M.W., Wallach D., Aderka D., Camp R.D. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994, 96(1):146-151.
18. Lew W., Bowcock A.M., Krueger J.G. Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and "Type 1" inflammatory gene expression. Trends Immunol 2004, 25(6):295-305. 10.1016/j.it.03.006.
19. Bonifati C., Ameglio F. Cytokines in psoriasis. Int J Dermatol 1999, 38(4):241-251.
20. Kristensen M., Chu C.Q., Eedy D.J., Feldmann M., Brennan F.M., Breathnach S.M. Localization of tumour necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor. Clin Exp Immunol 1993, 94(2):354-362.
21. Banno T., Gazel A., Blumenberg M. Effects of tumor necrosis factor-alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional profiling. J Biol Chem 2004, 279(31):32633-32642. 10.1074/jbc.M0.40064220.
22. Zhuang L., Ma W., Cai D., Zhong H., Sun Q. Associations between tumor necrosis factor-α polymorphisms and risk of psoriasis: a meta-analysis 2013, e68827. Public Library of Science. 10.1371/journal.pone.0068827. G. Novelli (Ed.).
23. Tejasvi T., Stuart P.E., Chandran V., Voorhees J.J., Gladman D.D., Rahman P., et al. TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis. J Invest Dermatol 2012, 132(3 Pt 1):593-600. 10.1038/jid.2011.376.
24. Sa S.M., Valdez P.A., Wu J., Jung K., Zhong F., Hall L., et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 2007, 178(4):2229-2240.
25. Tohyama M., Hanakawa Y., Shirakata Y., Dai X., Yang L., Hirakawa S., et al. IL-17 and IL-22 mediate IL-20 subfamily cytokine production in cultured keratinocytes via increased IL-22 receptor expression. Eur J Immunol 2009, 39(10):2779-2788. 10.1002/eji.200939473.
26. Kunz S., Wolk K., Witte E., Witte K., Doecke W.-D., Volk H.-D., et al. Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs. Exp Dermatol 2006, 15(12):991-1004. 10.1111/j.1600-0625.2006.00516.x.
27. Kumari S., Bonnet M.C., Ulvmar M.H., Wolk K., Karagianni N., Witte E., et al. Tumor necrosis factor receptor signaling in keratinocytes triggers interleukin-24-dependent psoriasis-like skin inflammation in mice. Immunity 2013, 39(5):899-911. 10.1016/j.immuni.2013.10.009.
28. Rømer J., Hasselager E., Nørby P.L., Steiniche T., Thorn Clausen J., Kragballe K. Epidermal overexpression of interleukin-19 and -20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine a or calcipotriol. J Invest Dermatol 2003, 121(6):1306-1311. 10.1111/j.1523-1747.2003.12626.x.
29. He M., Liang P. IL-24 transgenic mice: in vivo evidence of overlapping functions for IL-20, IL-22, and IL-24 in the epidermis. J Immunol 2010, 184(4):1793-1798. 10.4049/jimmunol.0901829.
30. Isaacs A., Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957, 147(927):258-267.
31. Jaeckel E., Cornberg M., Wedemeyer H., Santantonio T., Mayer J., Zankel M. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001, 345(20):1452-1457. 10.1056/NEJMoa011232.
32. Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology 2009, 49(5 (Suppl)):S103-S111. 10.1002/he22956.
33. La Mantia L., Capsoni F. Psoriasis during interferon beta treatment for multiple sclerosis. Neurol Sci 2010, 31(3):337-339. 10.1007/s10072-009-0184-x.
34. Afshar M., Martinez a D., Gallo R.L., Hata T.R. Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases. J Eur Acad Dermatol Venereol 2013, 27(6):771-778. 10.1111/j.1468-3083.2012.04582.x.
35. Nestle F.O., Conrad C., Tun-Kyi A., Homey B., Gombert M., Boyman O., et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005, 202(1):135-143. 10.1084/jem.20050500.
36. Tsoi L.C., Spain S.L., Knight J., Ellinghaus E., Stuart P.E., Capon F., et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet 2012, 44(12):1341-1348. 10.1038/ng.2467.
37. Bijlmakers M.-J., Kanneganti S.K., Barker J.N., Trembath R.C., Capon F. Functional analysis of the RNF114 psoriasis susceptibility gene implicates innate immune responses to double-stranded RNA in disease pathogenesis. Hum Mol Genet 2011, 20(16):3129-3137. 10.1093/hmg/ddr215.
38. Hida S., Ogasawara K., Sato K., Abe M., Takayanagi H., Yokochi T., et al. CD8(+) T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-alpha/beta signaling. Immunity 2000, 13(5):643-655.
39. van der Fits L., Mourits S., Voerman J.S.A., Kant M., Boon L., Laman J.D., et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 2009, 182(9):5836-5845. 10.4049/jimmunol.0802999.
40. Walter A., Schäfer M., Cecconi V., Matter C., Urosevic-Maiwald M., Belloni B., et al. Aldara activates TLR7-independent immune defence. Nat Commun 2013, 4:1560. 10.1038/ncomms2566.
41. Wohn C., Ober-Blöbaum J.L., Haak S., Pantelyushin S., Cheong C., Zahner S.P., et al. Langerin(neg) conventional dendritic cells produce IL-23 to drive psoriatic plaque formation in mice. Proc Natl Acad Sci U S A 2013, 110(26):10723-10728. 10.1073/pnas.1307569110.
42. Ueyama A., Yamamoto M., Tsujii K., et al. Mechanism of pathogenesis of imiquimod-induced skin inflammation in the mouse: a role for interferon-alpha in dendritic cell activation by imiquimod. J Dermatol 2014, 41(2):135-143. 10.1111/1346-8138.12367.
43. Bissonnette R., Papp K., Maari C., Yao Y., Robbie G., White W.I., et al. A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis. J Am Acad Dermatol 2010, 62(3):427-436. 10.1016/j.jaad.2009.05.042.
44. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005, 201(2):233-240. 10.1084/jem.20041257.
45. Qu N., Xu M., Mizoguchi I., Furusawa J., Kaneko K., Watanabe K., et al. Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory disease. Clin Dev Immunol 2013, 2013. Article ID 968549. 10.1155/2013/968549.
46. Fitch E., Harper E., Skorcheva I., Kurtz S.E., Blauvelt A. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep 2007, 9(6):461-467.
47. Lee E., Trepicchio W.L., Oestreicher J.L., Pittman D., Wang F., Chamian F., et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004, 199(1):125-130. 10.1084/jem.20030451.
48. Pantelyushin S., Haak S., Ingold B., Kulig P., Heppner F.L., Navarini A.A., et al. Rorγt+ innate lymphocytes and γδ T cells initiate psoriasiform plaque formation in mice. J Clin Invest 2012, 122(6):2252-2256. 10.1172/JCI61862.
49. Guo X., Jiang X., Xiao Y., Zhou T., Guo Y., Wang R., et al. IL-17A signaling in colonic epithelial cells inhibits pro-inflammatory cytokine production by enhancing the activity of ERK and PI3K, Mizoguchi E, ed. PLOS ONE 2014, 9(2):e89714. 10.1371/journal.pone.0089714.
50. Wedebye Schmidt E.G., Larsen H.L., Kristensen N.N., Poulsen S.S., Lynge Pedersen A.M., Claesson M.H., et al. TH17 cell induction and effects of IL-17A and IL-17F blockade in experimental colitis. Inflamm Bowel Dis 2013, 19(8):1567-1576. 10.1097/MIB.0b013e318286fa1c.
51. McLean L.P., Cross R.K., Shea-Donohue T. Combined blockade of IL-17A and IL-17F may prevent the development of experimental colitis. Immunotherapy 2013, 5(9):923-925. 10.2217/imt.13.87.
52. Tse M.T. IL-17 Antibodies Gain Momentum 2014, 815-816. Nature Publishing Group. 10.1038/nrd 4152.
53. Yarilina A., Ivashkiv L.B. Type I interferon: a new player in TNF signaling. Curr Dir Autoimmun 2010, 11:94-104. 10.1159/900028919.
54. Rosengren S., Corr M., Firestein G.S., Boyle D.L. The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. Ann Rheum Dis 2012, 71(3):440-447. 10.1136/ard.2011.841502.
55. Huys L., Van Hauwermeiren F., Dejager L., Dejonckheere E., Lienenklaus S., Weiss S., et al. Type I. interferon drives tumor necrosis factor-induced lethal shock. J Exp Med 2009, 206(9):1873-1882. 10.1084/jem.20090213.
56. Angelot F., Seillès E., Biichlé S., Berda Y., Gaugler B., Plumas J., et al. Endothelial cell-derived microparticles induce plasmacytoid dendritic cell maturation: potential implications in inflammatory diseases. Haematologica 2009, 94(11):1502-1512. 10.3324/haematol.2009.340109.
57. Palucka A.K., Blanck J.-P., Bennett L., Pascual V., Banchereau J. Cross-regulation of T.N.F. IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA 2005, 102(9):3372-3377. 10.1073/pnas.0408506102.
58. Ju X., Zenke M., Hart D.N.J., Clark G.J. CD300a/c regulate type I interferon and TNF-alpha secretion by human plasmacytoid dendritic cells stimulated with TLR7 and TLR9 ligands. Blood 2008, 112(4):1184-1194. 10.1182/blood-2007-12-511279.
59. Dutz J.P. Tumor necrosis factor-a inhibition and palmoplantar pustulosis: Janus-faced therapy?. J Rheumatol 2007, 34(2):247-249.
60. Alekseyenko A.V., Perez-Perez G.I., De Souza A., Strober B., Gao Z., Bihan M., et al. Community differentiation of the cutaneous microbiota in psoriasis. Microbiome 2013, 1(1):31. 10.1186/2049-1-312618.
61. Trivedi B., Microbiome: The surface brigade. Nature 2012, 492(7429):S60-S61. 10.10/492S60a1038.
62. Castelino M., Eyre S., Upton M., Ho P., Barton A. The bacterial skin microbiome in psoriatic arthritis, an unexplored link in pathogenesis: challenges and opportunities offered by recent technological advances. Rheumatology 2014, 53(5):777-784. 10.1093/rheumatology/ket319.
63. Mavragani C.P., La D.T., Stohl W., Crow M.K. Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort. Arthritis Rheum 2010, 62(2):392-401. 10.1002/art.62722.
64. Raterman H.G., Vosslamber S., de Ridder S., Nurmohamed M.T., Lems W.F., Boers M., et al. The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther 2012, 14(2):R95. 10.1186/ar3819.
65. Keeley K., Bell J. The immunological basis for treatment resistance to anti-TNF treatments. ClinicalTrials.gov [Internet] 2014, National Library of Medicine (US), Bethesda (MD), 2000-[cited 2014 August 28] Available from: http://clinicaltrials.gov/show/NCT01971346NLM identifier: NCT01971346.
66. Biophysical and physiological effects of solar radiation on human skin 2007, Royal Society of Chemistry, Cambridge. 10.1039/9781847557957. P.U. Giacomoni (Ed.).
67. Haig D.M., Hutchison G., Green I., Sargan D., Reid H.W. The effect of intradermal injection of GM-CSF and TNF-α on the accumulation of dendritic cells in ovine skin. Vet Dermatol 2008, 6(4):211-220. 10.1111/j.1365-3164.1995.tb00067.x.
68. Antonopoulos C., Cumberbatch M., Dearman R.J., Daniel R.J., Kimber I., Groves R.W. Functional caspase-1 is required for langerhans cell migration and optimal contact sensitization in mice 2001, 3672-3677. American Association of Immunologists. 10.4049/jimmunol.166.6.
69. Cho K.-A., Suh J.W., Lee K.H., Kang J.L., Woo S.Y. IL-17 and IL-22 enhance skin inflammation by stimulating the secretion of IL-1β by keratinocytes via the ROS-NLRP3-caspase-1 pathway. Int Immunol 2012, 24(3):147-158. 10./intimm/dxr1101093.
70. Maione F., Paschalidis N., Mascolo N., Dufton N., Perretti M., D'Acquisto F. Interleukin 17 sustains rather than induces inflammation. Biochem Pharmacol 2009, 77(5):878-887. 10.1016/j.bcp.11.0112008.
71. Albanesi C., Scarponi C., Cavani A., Federici M., Nasorri F., Girolomoni G. Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-gamma- and interleukin-4-induced activation of human keratinocytes. J Invest Dermatol 2000, 115(1):81-87. 10.1046/j.1523-1747.2000.1.x0004.
72. Griffin G.K., Newton G., Tarrio M.L., Bu D., Maganto-Garcia E., Azcutia V., et al. IL-17 and TNF-α sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation. J Immunol 2012, 188(12):6287-6299. 10.4049/jimmunol.1200385.
73. Wang C.Q.F., Akalu Y.T., Suarez-Farinas M., Gonzalez J., Mitsui H., Lowes M.A., et al. IL-17 and TNF synergistically modulate cytokine expression while suppressing melanogenesis: potential relevance to psoriasis. J Invest Dermatol 2013, 133(12):2741-2752. 10.1038/jid.2013237.
74. Ruddy M.J., Shen F., Smith J.B., Sharma A., Gaffen S.L. Interleukin-17 regulates expression of the CXC chemokine LIX/CXCL5 in osteoblasts: implications for inflammation and neutrophil recruitment. J Leukoc Biol 2004, 76(1):135-144. 10.1189/jlb.0204065.
75. Nonaka M., Ogihara N., Fukumoto A., Sakanushi A., Kusama K., Pawankar R., et al. Synergistic induction of macrophage inflammatory protein-3α/CCL20 production by interleukin-17A and tumor necrosis factor-A; in nasal polyp fibroblasts. World Allergy Organ J 2009, 2(10):218-223. 10.1097/WOX.0b013e3181bdd219.
76. Iyoda M., Shibata T., Kawaguchi M., Hizawa N., Yamaoka T., Kokubu F., et al. IL-17A and IL-17F stimulate chemokines via MAPK pathways (ERK1/2 and p38 but not JNK) in mouse cultured mesangial cells: synergy with TNF-alpha and IL-1beta. Am J Physiol Renal Physiol 2010, 298(3):F779-F787. 10.1152/ajprenal.00198.2009.
77. Koenders M.I., Marijnissen R.J., Devesa I., Lubberts E., Joosten L.A., Roth J., et al. Tumor necrosis factor-interleukin-17 interplay induces S100A8, interleukin-1β, and Matrix metalloproteinases, and drives irreversible cartilage destruction in murine arthritis: rationale for combination treatment during arthritis. Arthritis Rheum 2011, 63(8):2329-2339. 10.1002/art.30418.
78. Mose M., Kang Z., Raaby L., Iversen L., Johansen C. TNFα- and IL-17A-mediated S100A8 expression is regulated by p38 MAPK. Exp Dermatol 2013, 22(7):476-481. 10.1111/exd.12187.
79. Donetti E., Cornaghi L., Gualerzi A., Baruffaldi Preis F.W., Prignano F. An innovative three-dimensional model of normal human skin to study the proinflammatory psoriatic effects of tumor necrosis factor-alpha and interleukin-17. Cytokine 2014, 68(1):1-8. 10.1016/j.cyto.2014.03.003.
80. Covagen Covagen initiates phase Ib/IIa study of bispecific anti-TNF/IL-17A FynomAb COVA322. Reuters May 2014.
81. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002, 8(5):500-508. 10.1038/nm0502-500.
82. Tzartos J.S., Friese M.A., Craner M.J., Palace J., Newcombe J., Esiri M.M., et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008, 172(1):146-155. 10.2353/ajpath.2008.070690.
83. Brucklacher-Waldert V., Stuerner K., Kolster M., Wolthausen J., Tolosa E. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain 2009, 132(Pt 12):3329-3341. 10.1093/brain/awp289.
84. Kostic M., Dzopalic T., Zivanovic S., Zivkovic N., Cvetanovic A., Stojanovic I., et al. IL-17 and glutamate excitotoxicity in the pathogenesis of multiple sclerosis. Scand J Immunol 2014, 79(3):181-186. 10.1111/sji.12147.
85. Matusevicius D., Kivisäkk P., He B., Kostulas N., Ozenci V., Fredrikson S., et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999, 5(2):101-104.
86. Murugaiyan G., Mittal A., Lopez-Diego R., Maier L.M., Anderson D.E., Weiner H.L. IL-27 is a key regulator of IL-10 and IL-17 production by human CD4+ T cells. J Immunol 2009, 183(4):2435-2443. 10.4049/jimmunol.0900568.
87. Gu Y., Yang J., Ouyang X., Liu W., Li H., Yang J., et al. Interleukin 10 suppresses Th17 cytokines secreted by macrophages and T cells. Eur J Immunol 2008, 38(7):1807-1813. 10.1002/eji.200838331.
88. Zhang X., Markovic-Plese S. Interferon beta inhibits the Th17 cell-mediated autoimmune response in patients with relapsing-remitting multiple sclerosis. Clin Neurol Neurosurg 2010, 112(7):641-645. 10.1016/j.clineuro.2010.04.020.
89. Alexander J.S., Harris M.K., Wells S.R., Mills G., Chalamidas K., Ganta V.C., et al. Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b. Mult Scler 2010, 801-809. 10.1177/1352458510370791.
90. Axtell R.C., de Jong B.A., Boniface K., van der Voort L.F., Bhat R., De Sarno P., et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010, 16(4):406-412. 10.1038/nm.2110.
91. Bălaşa R., Bajko Z., Huţanu A. Serum levels of IL-17A in patients with relapsing-remitting multiple sclerosis treated with interferon-β. Mult Scler 2013, 19(7):885-890. 10.1177/1352458512468497.
92. Rácz E., Prens E.P., Kurek D., Kant M., de Ridder D., Mourits S., et al. Effective treatment of psoriasis with narrow-band UVB phototherapy is linked to suppression of the IFN and Th17 pathways. J Invest Dermatol 2011, 131(7):1547-1558. 10.1038/jid.2011.53.
93. Gregorio J., Meller S., Conrad C., Di Nardo A., Homey B., Lauerma A., et al. Plasmacytoid dendritic cells sense skin injury and promote wound healing through type I interferons. J Exp Med 2010, 207(13):2921-2930. 10.1084/jem.20101102.
94. Tohyama M., Yang L., Hanakawa Y., Dai X., Shirakata Y., Sayama K. IFN-A enhances IL-22 receptor expression in keratinocytes: a possible role in the development of psoriasis. J Invest Dermatol 2012, 1933-1935. 10.1038/jid.2011.468.
95. Guilloteau K., Paris I., Pedretti N., Boniface K., Juchaux F., Huguier V., et al. Skin inflammation induced by the synergistic action of IL-17A, IL-22, oncostatin M, IL-1{alpha}, and TNF-{alpha} recapitulates some features of psoriasis. J Immunol 2010, 10.4049/jimmunol.0902464.
96. Van der Fits L., van der Wel L.I., Laman J.D., Prens E.P., Verschuren M.C.M. In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered. J Invest Dermatol 2004, 122(1):51-60. 10.1046/j.0022-202X.2003.22113.x.
97. Christophers E., Metzler G., Röcken M. Bimodal immune activation in psoriasis. Br J Dermatol 2014, 170(1):59-65. 10.1111/bjd.12631.
98. Mountz J.D., Wang J.H., Xie S., Hsu H.-C. Cytokine regulation of B-cell migratory behavior favors formation of germinal centers in autoimmune disease. Discov Med 2011, 11(56):76-85.
99. Gallo E., Cabaleiro T., Román M., Solano-López G., Abad-Santos F., García-Díez A., et al. The relationship between tumour necrosis factor (TNF)-α promoter and IL12B/IL-23R genes polymorphisms and the efficacy of anti-TNF-α therapy in psoriasis: a case-control study. Br J Dermatol 2013, 169(4):819-829. 10.1111/bjd.12425.